Glo-BNHL is an international academic-led industry-collaborative early phase clinical trial developed by ITCC*, EICNHL** and COG*** and designed to efficiently assess multiple prioritised novel agents in paediatric patients with relapsed and refractory B-NHL. It is sponsored by the University of Birmingham and managed by the Cancer Research UK Clinical Trials Unit (CRCTU) in Birmingham.
The concept was developed by the International ACCELERATE B-NHL Working Group formed at the 2nd ACCELERATE Paediatric Strategy Forum. Designed to overcome the challenges of too many potential new drugs to be tested in very small international population of children with relapsed and refractory mature B-cell malignancies, this trial relies on international collaboration, a Platform-trial infrastructure and a robust drug-prioritisation strategy to achieve its goals.
The Trial Steering Committee which includes globally-representative academic clinicians from ITCC, EICNHL and COG, are very keen to discuss any potential assets of any class that may be suitable for inclusion in the trial at an early stage of development. If you are interested in finding out more please email: Glo-BNHL@trials.bham.ac.uk and we will send you the full information pack.